[Form 4] Solid Biosciences Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filed for Ilan Ganot (director) reports option and restricted stock unit grants on 08/14/2025. The reporting person received an employee stock option to buy 37,500 shares at an exercise price of $6.17, exercisable through 08/14/2035. In addition, 18,750 restricted stock units (RSUs) were granted, each representing the contingent right to one share. Both holdings are reported as indirectly beneficially owned (I) via wife. The RSUs and option vest over four years, with 50% vesting on the second anniversary of the August 14, 2025 grant date and 25% each year thereafter. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Ganot on 08/18/2025.

Positive

• Grants disclosed clearly: Option for 37,500 shares at $6.17 and 18,750 RSUs were reported.
• Vesting schedule provided: Awards vest over four years with 50% on second anniversary then 25% annually, supporting retention alignment.
• Indirect ownership disclosed: Both holdings are reported as beneficially owned indirectly via spouse.
• Complete contract terms: Option term explicitly ends 08/14/2035, giving clear exercisability timeframe.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine equity compensation grant for a director; establishes potential future share issuance if exercised or settled.

The filing documents customary long-term incentive awards: a 10-year option for 37,500 shares at $6.17 and 18,750 RSUs. Vesting is time-based with a deferred schedule concentrated at the 2-year anniversary (50%) then annual 25% tranches, which supports retention. The awards are reported as indirectly owned through the reporting person's spouse, consistent with personal planning. From a capital-structure view, these are dilutive only if exercised or settled; the filing discloses quantities and explicit vesting/term details investors need to model potential future share count changes.

Corporate Governance Expert

TL;DR: Board director received standard equity-based compensation with multi-year vesting to align interests with shareholders.

The disclosure shows governance-aligned compensation design: time-vesting RSUs plus an option that vests over four years, encouraging continued service through the vesting horizon. Reporting as indirect ownership by spouse is appropriately disclosed. The Form 4 is complete in describing grant amounts, exercise price, exercisability window, and vesting schedule, enabling transparency on insider incentives and timing of potential share issuance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ganot Ilan

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$6.17	08/14/2025		A		37,500		(1)	08/14/2035	Common Stock	37,500	$0.00	37,500	I	Wife
Restricted Stock Units	(2)	08/14/2025		A		18,750		(1)	(1)	Common Stock	18,750	$0.00	18,750	I	Wife

Explanation of Responses:

1. The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary.

2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

	/s/ David Tyronne Howton as attorney-in-fact for Ilan Ganot	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Ilan Ganot report on the Form 4 for SLDB?

The Form 4 reports an employee stock option for 37,500 shares at $6.17 and 18,750 RSUs, both granted on 08/14/2025.

When do the option and RSUs vest for the grants reported by Ilan Ganot?

They vest over four years: 50% on the second anniversary of the 08/14/2025 grant date, then 25% on each subsequent anniversary until year four.

How are the reported securities owned according to the Form 4?

Both the option and the RSUs are reported as indirect beneficial ownership (I) through the reporting person's wife.

What is the exercise price and expiration for the option reported by Ilan Ganot?

The option has an exercise price of $6.17 and an expiration/exercisable window through 08/14/2035.

Who signed the Form 4 and when was it filed?

The Form 4 was signed by David Tyronne Howton as attorney-in-fact for Ilan Ganot and dated 08/18/2025.